Search

The traditional use of plants of the Cinnamomum genus dates back to traditional Eastern medicine for millennia and they have also been used in Western integrative medicine practices, especially for their anti-inflammatory activity. In the context of chemical diversity, the absolute majority of species in this genus have cinnamaldehyde as the majority component, which in turn holds the title of the active ingredient, whose biological effect profile has already been demonstrated in numerous experiments in acute and chronic inflammatory conditions. In this context, the objective of this research was to investigate how cinnamaldehyde can influence inflammatory phenomena. To this end, the data search was carried out in Pub- Med, SciELO, and LILACS databases using the following descriptors: "cinnamaldehyde OR cinnamaldehyde" and "inflammation". Next, the methodological quality of the selected articles was checked, excluding repeated studies, which were purely in silico and not relevant to the construction of this research. The findings showed cinnamaldehyde to modulate the inflammatory response by inhibiting pro-inflammatory mediators and important signaling trajectories, including NF-κB, NLRP3 inflammasome, TGF-β/Smads, and the NRF2/ARE antioxidant pathway. Cinnamaldehyde's scope of investigation also involves aspects of translational science, exhibiting therapeutic effects in human models, which suggests that it may have clinical relevance. The data support that cinnamaldehyde is a promising candidate for development as a treatment in inflammatory pathologies., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Mimosa caesalpiniifolia (Fabaceae) is used by Brazilian people to treat hypertension, bronchitis, and skin infections. Herein, we evaluated the antiproliferative action of the dichloromethane fraction from M. caesalpiniifolia (DFMC) stem bark on murine tumor cells and the in vivo toxicogenetic profile. Initially, the cytotoxic activity of DFMC on primary cultures of Sarcoma 180 (S180) cells by Alamar Blue, trypan, and cytokinesis block micronucleus (CBMN) assays was assessed after 72 h of exposure, followed by the treatment of S180-bearing Swiss mice for 7 days, physiological investigations, and DNA/chromosomal damage. DFMC and betulinic acid revealed similar in vitro antiproliferative action on S180 cells and induced a reduction in viable cells, induced a reduction in viable cells and caused the emergence of bridges, buds, and morphological features of apoptosis and necrosis. S180-transplanted mice treated with DFMC (50 and 100 mg/kg/day), a betulinic acid-rich dichloromethane, showed for the first time in vivo tumor growth reduction (64.8 and 80.0%) and poorer peri- and intratumor quantities of vessels. Such antiproliferative action was associated with detectible side effects (loss of weight, reduction of spleen, lymphocytopenia, and neutrophilia and increasing of GOT and micronucleus in bone marrow), but preclinical general anticancer properties of the DFMC were not threatened by toxicological effects, and these biomedical discoveries validate the ethnopharmacological reputation of Mimosa species as emerging phytotherapy sources of lead molecules., Competing Interests: The authors declare that there are no conflicts of interest regarding the publication of this paper., (Copyright © 2021 Paulo Michel Pinheiro Ferreira et al.)